Compare BUI & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUI | ANGO |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.7M | 530.2M |
| IPO Year | N/A | 2004 |
| Metric | BUI | ANGO |
|---|---|---|
| Price | $27.10 | $10.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 59.8K | ★ 858.7K |
| Earning Date | 01-01-0001 | 01-06-2026 |
| Dividend Yield | ★ 6.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | N/A | ★ $307,306,000.00 |
| Revenue This Year | N/A | $9.11 |
| Revenue Next Year | N/A | $4.94 |
| P/E Ratio | $7.77 | ★ N/A |
| Revenue Growth | N/A | ★ 7.26 |
| 52 Week Low | $18.73 | $8.27 |
| 52 Week High | $24.22 | $13.99 |
| Indicator | BUI | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 36.57 |
| Support Level | $26.15 | $10.16 |
| Resistance Level | $26.67 | $10.90 |
| Average True Range (ATR) | 0.26 | 0.49 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 96.79 | 31.24 |
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing of writing (selling) call and put options.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.